Moreover, although effective in first-line treatment of hepatocellular carcinoma, the combination of anti-VEGF and anti-PD-1/PD-L1 agents (which will be discussed in the next section of this review) has yet to be studied in first-line treatment of advanced GEJ and GC [27]. The gene discussed is VEGFA; the disease is gastric cancer.